Groundbreaking Phase 3 Trial Reveals Benefits of Trastuzumab Deruxtecan in HER2-Mutant Lung Cancer #South_Korea #Seoul #Trastuzumab_Deruxtecan #HER2-Mutant_NSCLC #DESTINY-Lung04